Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands

Leila Rostamizadeh ¹ , Ommoleila Molavi ^2,3 * , Mohsen Rashid ¹, Fatemeh Ramazani ¹, Behzad Baradaran ⁴, Afsaneh Lavasanaifar ⁵, Raymond Lai ⁶

Cited by CrossRef: 4

1- Ye Z, Ding J, Huang J, Hu Z, Jin F, Wu K. Ginsenoside Rg3 activates the immune function of CD8+ T cells via circFOXP1-miR-4477a-PD-L1 axis to induce ferroptosis in gallbladder cancer. Arch Pharm Res. 2024;47(10-11):793 [Crossref]

2- Liu S, Zhang J, Zhang N, Meng X, Liu K, Yang Y, Sun T, Sun L. Vibratome sectioning of tumors to evaluate the interactions between nanoparticles and the tumor microenvironment ex-vivo. Front Bioeng Biotechnol. 2022;10 [Crossref]

3- Chakraborty S, Ye J, Wang H, Sun M, Zhang Y, Sang X, Zhuang Z. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy. Front Immunol. 2023;14 [Crossref]

4- Zhang J, Zhou L, Sun X, Lin Y, Yuan J, Yang C, Liao C. SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity. Cancer Biology & Therapy. 2024;25(1) [Crossref]

Submit Your Paper Instructions for Authors Aims and Scope Editorial Board Editorial Policies Publication Ethics Policies Editorial Board Policy Abstracting and Indexing Archive

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences.
Acceptance rate: 24%
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded, Google Scholar; SJR ; Essential Science Indicators; Publons; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO; Ulrich
Member of COPE
Follower of ICMJE
Permission: Creative Commons